Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Generics
Illinois, USA-based Long Grove Pharmaceuticals, founded in 2019 by strategic health care investor Water Street Healthcare Partners, will begin shipping its first products in mid-2022. 22 April 2022
Pharmaceutical
Research from industry analyst GlobalData has highlighted the limited impact that Western sanctions have had on foreign innovator drugs in Russia. 22 April 2022
Biotechnology
US biotech Terran Biosciences, which is focussed on therapeutics for neurological and psychiatric diseases, has entered into an agreement with French pharma major Sanofi for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets. 22 April 2022
Pharmaceutical
The pandemic has wreaked havoc on lives and economies, as well as the cost of healthcare, though benefiting the drugmakers that have pushed through new products to deal with the situation at record speed. 21 April 2022
Pharmaceutical
Privately-held Italian drugmaker Zambo today announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to colistimethate sodium powder for nebulization solution (CMS I-neb) for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa. 21 April 2022
Biotechnology
US neurotology company Otonomy closed 6% higher on Wednesday after presenting positive top-line results from the Phase IIa clinical trial of OTO-413 in subjects with hearing loss. 21 April 2022
Biotechnology
Top-line data for an mRNA-based COVID-19 vaccine from Arcturus Therapeutics have failed to impress investors, with the firm reporting 55% efficacy in the prevention of symptomatic disease. 21 April 2022
Pharmaceutical
Results from a pooled analysis of Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) show certain organ clinical responses correlated with clinically-meaningful changes in patient-reported outcomes (PROs). 21 April 2022
Biotechnology
The New England Journal of Medicine has published detailed results from the PROVENT Phase III study of AstraZeneca’s coronavirus antibody therapy Evusheld (tixagevimab/cilgavimab). 21 April 2022
Biotechnology
US biotech firm Tessera Therapeutics, which is pioneering a new approach in genetic medicine known as GENE WRITING technology, has raised over $300 million in Series C financing. 21 April 2022
Generics
India is well on its way to becoming a global hub for pharmaceuticals. Around 35 active pharmaceutical ingredients (API), which were previously imported into India, are now being manufactured across the country. Applied research for investigational new drugs has also quadrupled in India, reports The Pharma Letter’s India correspondent. 21 April 2022
Pharmaceutical
Ireland-headquartered Endo International yesterday announced that the US Tennessee Court of Appeals has reversed a trial court judge's order denying a motion for recusal by Endo's wholly-owned subsidiaries Endo Health Solutions and Endo Pharmaceuticals (collectively Endo) in Clay County et al v Purdue Pharma, et al, pending in the Circuit Court for Cumberland County, Tennessee, and remanded the case for transfer to a different judge. 21 April 2022
Pharmaceutical
Florida, USA-based biotech Hesperos has published early-stage research into a novel drug development technology that has caught the attention of French pharma major Sanofi. 21 April 2022
Pharmaceutical
The Indian subsidiary of German family-owned drug major Boehringer Ingelheim has urged drug authorities to put in place a system that will inform patent holders whenever an application is filed by local drugmakers for generic versions of patented molecules 20 April 2022
Biotechnology
Sweden’s BioArctic saw its shares fall 14.6% to 90.10 kronor today, after it revealed that US pharma major AbbVie has decided to terminate its collaboration on the portfolio of alpha-synuclein antibodies, including ABBV-0805. 20 April 2022
Biotechnology
USA-based Satellite Bio has emerged from stealth to reveal its ‘Tissue Therapeutics’ that are bioengineered to repair, restore or replace critical organ or tissue function. 20 April 2022
Biotechnology
Shares of USA-based AlloVir shot up more than 46% to $7.90 in mid-morning trading, after it announced that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel. 20 April 2022
Biotechnology
At the same time as announcing strategic financing agreements worth $260 million, USA-based BioXcel Therapeutics has announced the formation of wholly-owned subsidiary OnkosXcel Therapeutics to develop transformative medicines in oncology. 20 April 2022
Pharmaceutical
Gulf Pharmaceutical Industries Julphar, one of the largest pharmaceutical companies in the Middle East and Africa, has announced its Strategy 2030 to drive transformation through sustainable growth and deliver enhanced value for all stakeholders. 20 April 2022
Biotechnology
The Japanese business of Swiss biotech Idorsia has launched Pivlaz (clazosentan), a potent, selective endothelin A (ETA) receptor antagonist which targets the root cause of cerebral vasospasm. 20 April 2022
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Pharmaceutical
The Danish Ministry of Interior and Health has announced that the political parties have decided to permanently legalize treatment with medical cannabis in Denmark. 29 November 2024
Pharmaceutical
The currently available evidence is not sufficient to establish a causal relationship between the use of the antibiotic doxycycline and the risk of suicidality. 29 November 2024
Pharmaceutical
Taiwan-based Formosa Pharmaceuticals (6838: TW) revealed that it has entered into an exclusive licensing agreement with Medvisis Switzerland, in Switzerland and Liechtenstein, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative treatment of post-operative inflammation and pain following ocular surgery. 29 November 2024
Pharmaceutical
Industry is showing a very high level of readiness for upcoming new packaging and labelling measures impacting the UK market, according to the Medicines and Healthcare products Regulatory Agency (MHRA). 29 November 2024
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal has announced the pricing of 500 million-euro ($527.5 million) aggregate principal amount of 4.625% senior secured notes due 2031. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Pharmaceutical
The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to 4.75 years from the time a drug receives approval from global health authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), until it is approved by their local authority and is available on the market, writes The Pharma Letter's local correspondent. 28 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Pharmaceutical
A new indication for olverembatinib, developed by Suzhou-based Ascentage Pharma will be added to China’s National Reimbursement Drug List (NRDL) from next year. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Pharmaceutical
The first iteration of the European Shortages Monitoring Platform (ESMP) has gone live. 28 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze